Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Calpain-3 (CAPN3) is a muscle-specific, calcium-dependent cysteine protease essential for normal skeletal muscle function. It is unique among calpains due to its rapid self-autolysis and presence of specific insertion sequences (NS, IS1, IS2). CAPN3 is predominantly localized in the sarcomere, the basic contractile unit of muscle fibers, and is tightly regulated both by its own inhibitory fragments and interactions with sarcomeric proteins. CAPN3 regulates cytoskeletal remodeling, proteolytic turnover of structural proteins, and protein sumoylation, affecting muscle repair and maintenance. Mutations in the CAPN3 gene cause limb-girdle muscular dystrophy type 2A (LGMD2A), characterized by progressive weakness and wasting of the shoulder and pelvic girdle muscles. Despite its clear genetic link to disease, the endogenous substrates and precise medicine-relevant pathways of CAPN3 remain incompletely characterized, and no drugs specifically target this protease to date.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Calpain-3 (CAPN3).